We investigated the stereoselective inhibition of growth and ergosterol biosynthesis by SCH39304 in the pathogenic fungus Cryptococcus neoformans obtained from four AIDS patients who failed fluconazole therapy and compared the results to those obtained with a wild-type strain. For all strains, the MICs of the RR isomer were approximately half those of the racemate, with the SS enantiomer showing no inhibitory activity. The 50% inhibitory concentrations for in vitro ergosterol biosynthesis correlated with the MIC data, indicating stereoselective inhibition of their target P-450 enzyme, sterol 14␣-demethylase, as the cause of this difference. The RR enantiomer produced classical type II spectra on addition to microsomal extracts of the strains, whereas the SS enantiomer showed an absence of binding. Stereo-and regio-specific localization of N-1 substituent groups of SCH39304 within the active site of the enzyme determined the unique discrimination between its two enantiomers, and the inability to bind to sterol 14␣-demethylase is also true of other P-450 enzymes contained in the microsomal fraction. As previously observed for other antifungal azoles, isolates obtained following failure of fluconazole therapy showed resistance to SCH39304 and its RR enantiomer. This resistance could be associated with an alteration in the sensitivity of ergosterol biosynthesis in vitro. These alterations did not cause any changes allowing the SS enantiomer to bind to the P-450 mediating sterol 14␣-demethylation.
Cryptococcus neoformans is a pathogenic fungus which profits from impaired immune response systems in humans and hence is prevalent in AIDS patients and organ transplant recipients (4) . Current treatment of this fungal infection involves chemotherapy with azole antifungal drugs. Azole antifungal compounds inhibit the cytochrome P-450-dependent 14␣-demethylation of lanosterol or 24-methylene-24,25-dihydrolanosterol, resulting in a decreased availability of ergosterol, an essential membrane component, and a corresponding accumulation of 14␣-methylated sterols in cell membranes, which eventually leads to cell growth arrest (7) . Inhibition occurs through coordination of a nitrogen atom (at N-3 in imidazole and at N-4 in triazoles; Fig. 1 ) to the heme iron of the enzyme, with the N-1 substituent groups interacting with the apoprotein (13) . Additionally, the relative orientations of different N-1 substituent groups can influence antifungal activity, leading to further improvements in efficacy and selectivity (3, 14) . Yoshida and Aoyama (15) reported previously on four optical isomers of the agricultural fungicide triadimenol and their inhibition of sterol 14␣-demethylase isolated from Saccharomyces cerevisiae, with the 1S2R isomer having the greatest degree of potency. We have also screened a variety of azole antifungal enantiomers for their inhibitory activities against Candida albicans sterol 14␣-demethylase expressed in S. cerevisiae and reported extreme variations in the inhibitory activities of the enantiomers of SCH39304 (6). This report describes the stereospecific interaction of the enantiomers of SCH39304 ( Fig. 1 ) with the cytochrome P-450 monooxygenase system of the human pathogen C. neoformans and compares the interaction to that with a series of azole-tolerant C. neoformans strains described previously (10) .
MATERIALS AND METHODS
Strains. An azole-sensitive strain, strain B4500 (serotype D) (9) , and clinical isolates (serotype A) from four AIDS patients which showed resistance during fluconazole treatment (isolates R715, R716, R717 and R718) were used in the study. The strains were grown on YEPD medium, consisting of 2% (wt/vol) glucose, 2% (wt/vol) Difco peptone, and 1% (wt/vol) Difco yeast extract.
Inhibition of growth. MICs were estimated following inoculation of 5 ϫ 10 3 cells/ml in YEPD medium containing various doses of racemate or enantiomer. Incubation was at 37°C and 150 rpm in 60-ml containers (Sterilin, Shipley, United Kingdom) with 2 ml of culture. Growth was determined by cell counts and quantitation of the numbers of CFU after plating appropriate dilutions onto solid (2% Difco Bacto Agar) YEPD medium. The azole antifungal racemate and enantiomers were dissolved in dimethyl sulfoxide (DMSO) and were added prior to inoculation. Microsomal preparation. Cells from each strain were grown to the late logarithmic phase and were harvested by centrifugation at 1,500 ϫ g. Cells were resuspended in 100 mM potassium phosphate buffer containing 1 mM EDTA, 0.5 mM dithiothreitol, and 20% (vol/vol) glycerol. Cells were broken with a Braun homogenizer (Braun GmbH, Mesungen, Germany), and the cell debris was removed by centrifugation at 1,500 ϫ g for 10 min. The resulting supernatant was centrifuged at 10,000 ϫ g to remove mitochondria, and the microsomal pellet was prepared by a final centrifugation step at 100,000 ϫ g. Microsomal pellets were resuspended to a final protein concentration of 10 mg/ml, and the mixture was stored at Ϫ80°C until use. The protein concentration was determined by the method of Lowry et al. (11) .
Cytochrome P-450 content estimation. The cytochrome P-450 concentration was measured as described by Omura and Sato (12) . Microsomal suspensions reduced with sodium dithionite were transferred to two quartz cuvettes, and the baseline was recorded with a Philips PU8800 UV/VIS scanning spectrophotometer. The contents in the sample cuvette were bubbled with carbon monoxide for 45 s at a rate of one bubble per second, and the difference spectra were recorded.
Type II binding spectra. Microsomal suspensions (100 pmol/ml) were transferred into each of two quartz cuvettes, and a baseline was recorded from 350 to 500 nm. Difference spectra were then recorded after incremental additions of azole antifungal agents (dissolved in DMSO) to the test cuvette and after the addition of an equal volume of solvent to the reference cuvette by the method of Baldwin and Wiggins (1).
Sterol biosynthesis assay and inhibition studies.
Inhibition of CYP51 by azole antifungal agents was investigated by assessing the cell-free biosynthesis of ergosterol by the methods described previously (2, 10) . Cell extracts were prepared as described above for the microsomal preparations. The reaction mixture consisted of a cell extract (924 l/ml), cofactor solution (50 l; containing 1 mol of NADP ϩ , 1 mol of NADPH, 1 mol of NAD ϩ , 3 mol of glucose-6-phosphate, 5 mol of ATP, and 3 mol of reduced glutathione), divalent cation solution (10 l of 0.5 M MgCl 2 and 5 l of 0.4 M MnCl 2 ), 1 l of azole solution, and 10 l of [2- 14 C]mevalonate (0.25 Ci) (the reaction mixture was adjusted to pH 7 by the addition of 10 M KOH). The mixture was incubated at 37°C for 2 h with shaking (110 rpm), and the reaction was stopped by the addition of 1 ml of saponification reagent (15% [wt/vol] KOH in 90% [vol/vol] ethanol). Sterols were extracted in saponification reagent at 80°C for 45 min. Nonsaponifiable sterols were extracted three times with 5 ml of hexane and were dried under nitrogen. Samples were applied to thin-layer chromatography plates (ART 573; Merck) and were developed in cyclohexane-diethyl ether (5:1 [vol/vol]). Radioactive metabolites were located by autoradiography, and the ergosterol band was excised and radioactivity was assessed by liquid scintillation counting.
Chemicals. All chemicals were obtained from Sigma Chemical Company, Poole, United Kingdom, unless specified otherwise. [2- 14 C]mevalonate, dibenzethylenediamine salt (specific activity, 53 mCi/mmol), was obtained from Amersham, Amersham, United Kingdom. SCH39304 and pure enantiomers were gifts from Schering-Plough, Bloomfield, Ill. (Fig. 1) .
RESULTS
Effects of SCH39304 and enantiomers on growth. Growth rates for the azole-tolerant isolates R715, R716, R717, and R718 in YEPD medium were the same as that for azolesensitive isolate B4500, with a doubling time of 2 h. By using the racemate of SCH39304 as the inhibitor, a 10-fold difference in susceptibility was observed between the sensitive and resistant isolates (Table 1 ). Dramatic differences were observed between the individual enantiomers; the RR enantiomer was an effective inhibitor of the growth of all strains examined, with the azole-resistant isolates being 2.5-to 10-fold less sensitive than the sensitive strain to the compound. The SS enantiomer showed no inhibitory activity on the growth of any of the strains tested. An approximately twofold higher concentration of racemate compared to the concentration of the RR enantiomer was required for inhibition, as would be expected if only one enantiomer were active.
Inhibition of ergosterol biosynthesis. The inhibitory activities of azole antifungal agents on sterol 14␣-demethylation were tested with cell extracts from wild-type strain B4500 and the azole-tolerant isolates by measuring the incorporation of radioactivity from [2- Table 1 ). The SS enantiomer showed no inhibitory activity in all tests at concentrations up to 10 Ϫ3 M. The 50% inhibitory concentrations (IC 50 s) of the racemate and RR enantiomer were approximately 10-fold higher for the resistant isolates than for the sensitive isolate.
Stereoselective interaction of SCH39304 and its enantiomers with microsomal extracts. Cytochrome P-450 was detected in microsomal samples isolated from all strains. They displayed reduced carbon monoxide difference spectra, with a Soret maximum of 448 nm. A total of 100 pmol of microsomal cytochrome P-450 from each strain was used in subsequent experiments to investigate azole binding to the P-450(s) that was present. Incremental addition of the racemate or the RR enantiomer to microsomal extracts induced type II spectral changes, indicating binding to the heme as a sixth ligand. Induced type II spectra were characterized by a maximum at 428 nm and a minimum at 406 nm for all strains (Fig. 2) . The maximum concentration of DMSO used (1% [vol/vol]) caused no change in the spectrum over the region scanned. The SS enantiomer failed to induce a type II spectrum with microsomal extracts from all strains, reflecting the incompatibility of the stereochemical arrangement of the N-1 substituent group of this isomer for binding to the cytochrome P-450 apoproteins present in the microsomal fraction.
DISCUSSION
We have previously shown a unique variation in the inhibitory activity of the azole antifungal compound SCH39304 and its enantiomers in their ability to inhibit C. albicans sterol 14␣-demethylase when it is heterologously expressed in S. cerevisiae (6) . We investigated here their inhibition of microsomal P-450s present in the pathogenic fungus C. neoformans. The results obtained in this work reinforce the stereo-and regioselectivities of the RR enantiomer over those of the SS isomer in binding and inhibiting sterol 14␣-demethylase. Accordingly, the R configuration of the substituents at the azole chiral center prove decisive in interacting with the target P-450 enzyme. However, it is likely that a significant quantity of sterol 22-desaturase (P45061) is also present in fungal microsomal fractions (8) , so the results presented here have further implications than those presented previously (6) and were also extended to consideration of binding to the more resistant enzyme detected in isolates R715, R716, R717, and R718. Azole inhibition of sterol biosynthesis by using cell extracts reflected the pattern of activity obtained by treatment of cells. Disruption of cell membranes to produce the extract removes the possibility that influx and efflux mechanisms that select for the RR enantiomer and that remove the SS enantiomer, respectively, are explanations for the stereoselective inhibition. The RR enantiomer was shown to inhibit ergosterol biosynthesis in both the wild-type and resistant isolates, while the racemate was less effective in inhibiting ergosterol biosynthesis and the SS enantiomer was inactive. Again, this was explained by the fact that the RR form is the active inhibitor molecule of the racemate toward sterol 14␣-demethylase.
The RR enantiomer was shown to produce type II spectra on binding to microsomal P-450 isolated from each strain. However, the SS enantiomer failed to produce a binding spectrum, indicating no binding to P-450. The binding of the racemate to microsomal P-450 was observed to reach saturation at twice the molar concentration at which the RR enantiomer exhibited saturation (Fig. 3) . This is explained by the fact that the racemate consists of a 50:50 mixture of the RR and SS enantiomers, with only the RR enantiomer being an active inhibitor.
We have already shown that the azole tolerance of resistant isolates R715, R716, R717, and R718 toward ketoconazole, itraconazole, and fluconazole is most likely due to alterations at the active site of the target enzyme, sterol 14␣-demethylase, or to changes in the level of the enzyme(s) (10) . The results presented here augment this observation. It can also be concluded that if an alteration(s) in the apoprotein is the cause of resistance, the alteration is subtle, with the overall active-site conformation remaining conserved and the SS enantiomer continuing to be incapable of binding.
The enantiomers may interact with sterol 14␣-demethylase apoprotein through the chlorophenyl ring and the sulfonyl group. Molecular modeling of these enantiomers to the C. albicans enzyme suggests that the RR enantiomer is favored over the SS enantiomer by the sulfonyl moiety, which is positioned in the more hydrophilic channel leading towards the enzyme active site for the RR enantiomer (6). This deduction seems more plausible when comparing binding and inhibitory data for another azole antifungal compound, cyproconazole (5) . This molecule differs from SCH39304 by the replacement of the sulfonyl group for a cyclopropyl ring. Both the RR and the SS enantiomers of cyproconazole bind sterol 14␣-demethylase and have antifungal activities (5) . Consequently, it can be reasoned that in the SS enantiomer of SCH39304, the sulfonyl group is positioned into a hydrophobic region within the active site, which cannot be tolerated due to its polarity, and thus, the molecule fails to bind or show inhibitory activity against the treated cells.
It is concluded that stereo-and regiochemical differences within isomeric azole antifungal molecules have a profound effect on efficacy and selectivity. These differences may be exploited for selective inhibition of the fungal enzyme. The absence of binding of the SS enantiomer to sterol 14␣-demethylase of C. neoformans, as well as similar observations for sterol 14␣-demethylases isolated from a variety of different species, suggests a conservation of the three-dimensional structure around the active site of this enzyme throughout evolution.
